Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements align with provided Lipitor label excerpts (e.g., grapefruit juice CYP3A4 interaction, caution with substantial alcohol/liver history, contraindications and general statin mechanism/food timing). However, several alcohol-bleeding and clotting/muscle-damage/liver-damage risk claims are not supported by the provided label text, and some assertions are overly broad or framed as specific risks without label support.
Category Scores
Accurate Statements
Lipitor is a statin medication.
12.1 Mechanism of Action describes atorvastatin as an HMG-CoA reductase inhibitor (i.e., a statin).
Lipitor (atorvastatin) can interact with grapefruit or grapefruit juice.
7.2 Grapefruit Juice: components inhibit CYP 3A4 and increase plasma concentrations of atorvastatin.
Consuming excessive amounts of alcohol while taking Lipitor can lead to liver damage or liver disease.
5.2 Liver Dysfunction: Lipitor should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease; active liver disease is a contraindication.
Both alcohol and atorvastatin can affect the liver.
5.2 Liver Dysfunction: caution with substantial quantities of alcohol and/or history of liver disease; statins have been associated with liver function biochemical abnormalities.
Unsupported Statements
Alcohol and Lipitor (atorvastatin) can interact and these interactions may have negative effects on the body.
The provided label excerpts mention caution with substantial alcohol consumption and liver dysfunction, but do not explicitly describe a specific alcohol–atorvastatin interaction beyond that caution.
Alcohol can increase the risk of bleeding when taken with Lipitor.
The provided label excerpts do not state an alcohol-atorvastatin bleeding risk or bleeding risk specifically attributable to alcohol.
The increased bleeding risk with alcohol and Lipitor is especially noted in people who also take aspirin or other blood-thinning medications.
No provided label excerpt addresses aspirin/antithrombotic co-use with alcohol producing an increased bleeding risk for Lipitor.
Both alcohol and atorvastatin can affect blood clotting.
No provided label excerpt states that alcohol and/or atorvastatin affect blood clotting.
Both alcohol and atorvastatin can affect the liver.
While the label supports liver caution with alcohol and statin liver enzyme abnormalities, the statement is framed as broad equivalence (“both can affect the liver”) without specific label support for alcohol causing “liver damage” generally; support is limited to “caution” and contraindication context.
Drinking alcohol while consuming grapefruit or grapefruit juice with Lipitor can increase the risk of side effects such as muscle damage or liver damage.
The provided label supports grapefruit juice increasing atorvastatin concentrations (7.2), and statin myopathy/rhabdomyolysis/liver dysfunction warnings generally (5.1, 5.2), but it does not provide label support for a combined alcohol+grapefruit scenario increasing those specific adverse effects.
Contradictions
Important Omissions
No label-supported details about Lipitor dose or administration were provided (e.g., starting dose, dosing range, once-daily timing, with/without food), which is material if the question pertains to how to take Lipitor.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements introduce specific risks (bleeding/clotting; combined alcohol+grapefruit leading to muscle/liver damage) that are not supported by the provided label excerpts, which could mislead risk perception relative to on-label information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple alcohol-related claims (bleeding/clotting and specific co-medication association; combined alcohol+grapefruit adverse-effect risk) are not supported by the supplied label text.
Suggested Improvement
Limit alcohol statements to the label-supported liver warning language (caution in substantial alcohol consumption and history of liver disease; active liver disease is contraindicated) and limit grapefruit statements to its CYP3A4/atorvastatin concentration interaction; avoid specifying bleeding/clotting risks or combined alcohol+grapefruit adverse effects unless explicitly stated in the provided label excerpts.